Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Stage IV Pancreatic Cancer

Interventions: Biological: cixutumumab
Drug: erlotinib hydrochloride
Drug: gemcitabine hydrochloride

First Posted Date: 2008-02-18

Last Posted Date: 2022-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 134

Registration Number: NCT00617708

Locations: 🇺🇸
NEA Baptist Memorial Hospital, Jonesboro, Arkansas, United States
🇺🇸
Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
🇺🇸
Mills - Peninsula Hospitals, Burlingame, California, United States

and more 143 locations

Physical Activity in the Treatment of Obesity

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Diet plus continuous bouts
Behavioral: Diet plus short bouts
Behavioral: Diet plus moderate lifestyle activity

First Posted Date: 2008-02-14

Last Posted Date: 2017-09-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 177

Registration Number: NCT00615238

Locations: 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 1

Terminated

Conditions: Stage I Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Leukemia
Prolymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: obatoclax mesylate
Drug: fludarabine phosphate
Biological: rituximab
Other: laboratory biomarker analysis

First Posted Date: 2008-02-11

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00612612

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
Biological: ALVAC MART-1 Vaccine
Biological: aldesleukin
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2008-02-11

Last Posted Date: 2015-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT00612222

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Biological: Aldesleukin
Biological: ALVAC gp100 Vaccine

First Posted Date: 2008-02-07

Last Posted Date: 2015-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00610311

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Phase 1

Completed

Conditions: Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: cixutumumab
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2008-02-06

Last Posted Date: 2014-06-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT00609141

Locations: 🇺🇸
COG Phase I Consortium, Arcadia, California, United States

Antioxidant Treatment of Type 2 Diabetes

Early Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: n-aceylcysteine

First Posted Date: 2008-02-06

Last Posted Date: 2014-12-24

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 44

Registration Number: NCT00609102

Locations: 🇺🇸
Pacific Northwest Research Institute, Seattle, Washington, United States

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Immunoblastic Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Liver Carcinoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Grade 3 Follicular Lymphoma

Interventions: Drug: Dasatinib
Other: Pharmacological Study

First Posted Date: 2008-02-06

Last Posted Date: 2015-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00608361

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 20 locations

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage III Gastric Cancer
Stage IV Esophageal Cancer
Stage III Esophageal Cancer
Stage IV Gastric Cancer

Interventions: Drug: saracatinib

First Posted Date: 2008-02-06

Last Posted Date: 2018-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00607594

Locations: 🇺🇸
Hamilton Medical Center, Dalton, Georgia, United States
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 2 locations

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2

Completed

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: selumetinib
Other: pharmacological study

First Posted Date: 2008-01-30

Last Posted Date: 2014-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00604721

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy